Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...

A major UK study shows that commonly used home pulse oximeters can overestimate oxygen levels in people with darker skin, increasing the risk of undetected hypoxemia and raising urgent questions about ...

In the EXAKT study from the U.K., the home-use pulse oximeters assessed all gave higher oxygen saturation (SpO2) readings for patients with darker skin tones than for patients with lighter skin tones.

A total of 11,018 paired SpO2-SaO2 measurements were analysed. All five pulse oximeters returned higher SpO2 values for patients with darker skin tones than patients with lighter skin tones, at any ...

NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos. Cytokinetics has won FDA approval of its ...

Investing.com - H.C. Wainwright has reiterated its Buy rating and $120.00 price target on Cytokinetics (NASDAQ:CYTK), representing a significant upside from the current price of $53.89. According to ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...